News and Reports
FREE ROAD MAP TO FDA WHITE-PAPER
The ITC Transporter White Paper provides detailed guidance for transporter mediated DDI studies for the seven transporters recommended in the March 17, 2010 FDA Advisory Committee vote. Get the White Paper and a Road Map Summary to help navigate it.
QUESTIONS?
Speak with one of our transporter specialists about your needs to understand how we can help you and the results you can expect.
CONTACT OUR LAB:
888-OPTIVIA (888-678-4842)
Transporter News
2011
Optivia Transporter Newsletter Archives Informational newsletter with transporter related news including FDA and regulatory updates, upcoming conferences and recent literature.Read them here.
February 1, 2011
Transporter Guidance Article in February 2011 issue of Drug Discovery and Development Magazine by Dr. David Lustig, VP, BD of Optivia and Dr. Alan Mills. Read more....
March 17, 2010
FDA Advisory Committee Approves Recommendation for Routine Transporter DDI Assessment for New Drugs - FDA's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology voted to recommend NCE's be assessed for transporter mediated drug-interactions for the seven clinically relevant transporters in the ITC Transporter White Paper: P-gp ,BCRP, OAT1, OAT3, OCT2, OATP1B1 & OATP1B3.
March 1, 2010
The ITC Transporter White Paper Published The International Transporter Consortium published the Transporter White Paper in the March 2010 issue of Nature Reviews - Drug Discovery (Vol. 9, pp. 215 - 236). It details transporter DDI studies for clinical development and FDA submissions.
Click here to receive the full White Paper and a summary to locate key passages.